DrugPatentWatch Database Preview

LENVIMA Drug Profile

« Back to Dashboard

When do Lenvima patents expire, and when can generic versions of Lenvima launch?

Lenvima is a drug marketed by Eisai Inc and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seven patent family members in thirty countries.

The generic ingredient in LENVIMA is lenvatinib mesylate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.

Summary for LENVIMA

International Patents:	107
US Patents:	3
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	91
Clinical Trials:	10
Patent Applications:	81
Drug Prices:	Drug price information for LENVIMA
DailyMed Link:	LENVIMA at DailyMed

Generic Entry Opportunity Date for LENVIMA

NDA:

206947

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LENVIMA

Drug Class	Kinase Inhibitor
Mechanism of Action	Receptor Tyrosine Kinase Inhibitors

Synonyms for LENVIMA

4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide

4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide

4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide

4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide

4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide

4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide

4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide

4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide

417716-92-8

4CA-0485

716C928

A1-04306

A825653

ABP000863

AC-25047

AK175809

AKOS025401742

AN-6642

AOB87766

AS-16203

BC252209

BCP9000633

BCPP000247

BDBM50331094

CHEBI:85994

CHEMBL1289601

CS-0109

CTK1D4875

D09919

D0R0FO

DB-070219

DB09078

DTXSID50194605

E 7080

E-7080

E-7080, E7080

E7080

E7080 (Lenvatinib)

E7080, E 7080

E7080/E-7080

EE083865G2

ER-203492-00

EX-A249

FT-0700727

GTPL7426

HE068062

HE342379

HMS3244A07

HMS3244A08

HMS3244B07

HMS3654A14

HY-10981

J-513372

KB-78118

Kisplyx

KS-00000638

Lenvatinib

Lenvatinib (E7080)

Lenvatinib (USAN/INN)

Lenvatinib [USAN:INN]

Lenvatinib mesilate

Lenvatinib; E7080

LenvatinibE7080)

LEV

MFCD16038644

MLS006011239

MolPort-009-679-469

NCGC00263198-01

QCR-115

RS0099

s1164

SC-87813

SCHEMBL864638

SMR004702999

SYN1038

UNII-EE083865G2

WOSKHXYHFSIKNG-UHFFFAOYSA-N

ZINC3816292

US Patents and Regulatory Information for LENVIMA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No			Y	Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes

International Patents for LENVIMA

Country	Document Number	Estimated Expiration
Russian Federation	2328489
Taiwan	I304061
South Korea	100600550
Australia	2006236039
Japan	5190361
South Korea	20030040552

Supplementary Protection Certificates for LENVIMA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0764	Netherlands		PRODUCT NAME: LENVATINIB, EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1002/001 -002 20150528
2015 00053	Denmark		PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT DERAF, HERUNDER LENVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
/2015	Austria		PRODUCT NAME: LENVATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/15/1002/001-002 (MITTEILUNG) 20150601
90053-3	Sweden		PRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REG. NO/DATE: EU/1/15/1002 20150601
2015039	Lithuania		PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
2015039,C1698623	Lithuania		PRODUCT NAME: LENVATINIBAS; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528